Analysis of Potential Impact of COVID-19 on Compression Therapy Market

TMR

4 years ago

According to Transparency Market Research’s latest report on the global compression therapy market for the historical period 2017–2018 and forecast period 2019–2027, owing to rising sports injuries, increase in the number of orthopedic surgeries, and rapidly growing obese population boost demand for compression therapy products globally. However, lack of favorable reimbursement policies pertaining to vascular disease treatment with compression products would hamper market growth.
According to the report, the global compression therapy market was valued at US$ 3.2 Bn in 2018 and is anticipated to expand at a CAGR of 6.1% from 2019 to 2027

To know the scope of our report Get a Sample on Compression Therapy Market

Compression products are frequently used by athletes and sports persons as these reduce muscle pain, increase mobility, and enhance athletic performance. The most common causes of sports injuries are competitive, recreational or obligatory (physical education) activities. According to the Centers for Disease Control and Prevention (CDC), high school athletes alone account for 2 million injuries, 50,000 doctor visits, and 30,000 hospitalizations in the U.S. each year.
Hence, health care professionals (chiropractors and physiotherapists) extensively utilize these products for both amateur and professional sport patients and their regular clinic patients. Therefore, increasing number of sports injuries and growing preference by health care professionals are anticipated to increase the uptake of compression therapy products during the forecast period.

Obese people are at high risk of developing vascular diseases due to the pressure exerted by the weight of the body on the skin and underlying organs. According to the World Health Organization (2014), the prevalence of obesity had doubled since 1980. The WHO further stated that over 1.9 billion adults aged 18 years and above were reported to be overweight in 2014, of these over 600 million adults were obese. Furthermore, it is estimated that over 35% of the total population was obese in 2016.
This number is expected to increase during the forecast period. Therefore, rise in the obese population augments the uptake of compression therapy products in order to prevent vascular diseases.

Unfavorable reimbursement policies have played a crucial role in the compression therapy industry in the past few years. The treatment of vascular diseases with compression therapy products is expensive and requires large amount of money for follow-ups and monitoring of treatment. Hence, reimbursement is considered to be an essential aspect of the treatment. The Centers for Medicare and Medicaid Services (CMS) provides reimbursement only to patients who have undergone a four-week trial of conservative therapy before opting for intermittent pump.
Moreover, private insurers are adopting these reimbursement restrictions for compression therapy products to treat vascular disease. This factor is more prominent in developing nations such as India, China, Brazil, and Mexico due to low affordability to purchase highly expensive brand new compression devices.